Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas

Leiomyosarcoma (LMS) is a rare, aggressive, mesenchymal tumor. Subsets of LMS have been identified to harbor genomic alterations associated with homologous recombination deficiency (HRD); particularly alterations in BRCA2. Whereas genomic loss of heterozygosity (gLOH) has been used as a surrogate ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Seligson, Nathan D., Tang, Joy, Jin, Dexter X., Bennett, Monica P., Elvin, Julia A., Graim, Kiley, Hays, John L., Millis, Sherri Z., Miles, Wayne O., Chen, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038792/
https://www.ncbi.nlm.nih.gov/pubmed/35468996
http://dx.doi.org/10.1038/s41698-022-00271-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038792/
https://www.ncbi.nlm.nih.gov/pubmed/35468996
http://dx.doi.org/10.1038/s41698-022-00271-x

Ejemplares similares